Novo Nordisk A/S

Copenhagen Stock Exchange NOVO-B.CO

Novo Nordisk A/S Price to Sales Ratio (P/S) on January 14, 2025: 10.53

Novo Nordisk A/S Price to Sales Ratio (P/S) is 10.53 on January 14, 2025, a -23.65% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Novo Nordisk A/S 52-week high Price to Sales Ratio (P/S) is 19.07 on June 25, 2024, which is 81.05% above the current Price to Sales Ratio (P/S).
Novo Nordisk A/S 52-week low Price to Sales Ratio (P/S) is 10.53 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Novo Nordisk A/S average Price to Sales Ratio (P/S) for the last 52 weeks is 15.86.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Copenhagen Stock Exchange: NOVO-B.CO

Novo Nordisk A/S

CEO	Mr. Lars Fruergaard Jorgensen
IPO Date	Jan. 6, 2001
Location	Denmark
Headquarters	Novo Alle 1
Employees	71,880
Sector	Health Care
Industries Pharmaceuticals

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Key trends

Past 5 years